<span item_type="fundamental" item_id="83c63fb2925d7143883a63e0aa1b3c92" counter_id="ST/US/XAGEW" env="prod"></span><span item_type="announcement" item_id="582804946560225537" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 425.86 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.83.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -1.466 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Net Sales</strong>: For the three months ended September 30, 2025, net sales were $425,864, compared to $20,519 for the same period in 2024. For the nine months ended September 30, 2025, net sales were $1,439,829, compared to $32,839 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Gross Profit</strong>: For the three months ended September 30, 2025, gross profit was $254,463, compared to $15,679 for the same period in 2024. For the nine months ended September 30, 2025, gross profit was $826,944, compared to $27,707 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li><li><strong>Loss from Operations</strong>: For the three months ended September 30, 2025, loss from operations was - $1,471,017, compared to - $1,419,789 for the same period in 2024. For the nine months ended September 30, 2025, loss from operations was - $4,836,372, compared to - $3,991,621 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the nine months ended September 30, 2025, net cash used in operating activities was - $3,022,899, compared to - $3,121,193 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li><li><strong>Net Cash Used in Investing Activities</strong>: For the nine months ended September 30, 2025, net cash used in investing activities was - $164,224, compared to - $748,796 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: For the nine months ended September 30, 2025, net cash provided by financing activities was $4,139,212, compared to $2,094,853 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Inventory</strong>: As of September 30, 2025, inventory was $1,013,368, compared to $108,705 as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to continue the commercialization of its cosmetic products and anticipates revenue from the Elevai Acquisition, which had revenue of approximately $2.5 million in 2024, to assist in extending its cash runway.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring raising additional capital and anticipates the pending THPlasma Merger to close in the first quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1842939/000119312525283127/xage-20250930.htm"></span></li></ul>

LONGEVITY HEALTH HLDGS INC C/WTS 12/07/2028 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 425.86 K